EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Persistent Functional Impairment as an Early Indicator of Alzheimer Disease Pathology and Progression

Anhaltende funktionelle Einschränkung als früher Hinweis auf Alzheimer-Krankheits-Pathologie und -Progression

Maryam Ghahremani, Eric E Smith iD, Zahinoor Ismail iD

Journal of the American Geriatrics Society · 2026-02 · 74 (2) · 447-457

DOI: 10.1111/jgs.70247 ↗

Auf einen Blick

Bei 1.000 demenzfreien älteren Erwachsenen war persistierende funktionelle Einschränkung mit ungünstigeren CSF-AD-Biomarkern und höherer Demenzinzidenz verbunden. Vorübergehende Einschränkung zeigte keine signifikanten Biomarker-Assoziationen.

Fragestellung

Besteht bei demenzfreien älteren Erwachsenen ein Zusammenhang zwischen persistierender oder vorübergehender funktioneller Einschränkung und CSF-AD-Biomarkern sowie Demenzinzidenz?

Methode

Sekundäranalyse der Alzheimer's Disease Neuroimaging Initiative; 1.000 Teilnehmende; Querschnittsanalysen zu CSF-Biomarkern und Längsschnittanalyse zu inzidenter Demenz; adjustiert für Alter, Geschlecht, Bildung, APOE-ε4 und MMSE.

Ergebnisse

Persistierende FI vs. keine FI: Aβ42 niedriger (Beta −8,93; 95 %-KI −13,56 bis −4,03), p-tau181 höher (Beta 10,81; 95 %-KI 0,44–22,26) und ptau181/Aβ42 höher (Beta 21,66; 95 %-KI 7,02–38,31). Demenzinzidenz höher (HR 6,66; 95 %-KI 4,98–8,91).

Schlussfolgerung der Autor:innen

Die Autoren folgern, dass die Persistenz funktioneller Einschränkung die Prognose verbessert, indem Personen mit stärkerer AD-Pathologie und höherem Progressionsrisiko identifiziert werden.

Kernaussagen

  • Persistierende FI war mit ungünstigeren CSF-AD-Biomarkern assoziiert.
  • Vorübergehende FI zeigte keine signifikanten Biomarker-Assoziationen.
  • Persistierende FI war mit höherer Demenzinzidenz verbunden.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 15.12.2025. Verfasst von Maryam Ghahremani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIHR Exeter Biomedical Research Centre, Gordie Howe CARES, CIHR.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional impairment (FI) is a key criterion for diagnosing dementia. However, subtle functional changes may occur during preclinical and prodromal phases but may not be accurately characterized. Furthermore, research linking FI to Alzheimer disease (AD) biofluid biomarkers is limited. Here we examined cross‐sectional associations between cerebrospinal fluid (CSF) AD biomarkers and persistent versus transient FI in dementia‐free older adults, and the longitudinal association of FI with incident dementia.

Methods

Data from 1000 participants (age 72.9 ± 7.0; 45.2% female; 62.8% MCI) from the Alzheimer's Disease Neuroimaging Initiative were analyzed. CSF biomarkers included p‐tau181, Aβ42, and ptau‐181/Aβ42 ratio. Three Functional Activities Questionnaire items of “preparing a hot beverage,” “preparing a balanced meal,” and “shopping alone” were identified by factor analysis as assessing function rather than cognition directly. Persistent‐FI was operationalized as FI present at> two‐thirds of pre‐dementia visits. Comparator groups included Transient‐FI and No‐FI. Linear regression modeled the association between FI status and baseline biomarker levels, while Cox regression assessed the association between FI and incident dementia. Models adjusted for age, sex, education, APOE‐ε4 status, and MMSE.

Results

Compared to No‐FI, Persistent‐FI was associated with lower Aβ42 (Beta = −8.93; 95% CI: −13.56 to −4.03; p < 0.001), higher p‐tau181 (Beta = 10.81; 95% CI: 0.44–22.26; p = 0.041), and ptau181/Aβ42 ratio (Beta = 21.66; 95% CI: 7.02–38.31; p = 0.003). In contrast, Transient‐FI showed no significant associations. APOE‐ε4 carrier status was more prevalent in the Persistent‐FI group compared to No‐FI ( p = 0.009), but not in Transient‐FI ( p = 0.931). Compared to No‐FI, Persistent‐FI had a 6.66‐fold greater dementia incidence rate (95% CI: 4.98–8.91, p < 0.001), while Transient‐FI had a 1.72‐fold greater incidence rate (95% CI: 1.09–2.72, p = 0.021).

Conclusions

Findings extend the limited research on the association of FI with CSF AD biomarkers in dementia‐free populations. Operationalizing FI‐related risk by persistence enhances prognostication, identifying individuals with greater AD pathology and progression risk. This approach could enhance screening, early detection, and risk stratification, informing timely interventions before dementia onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansFemaleMaleAgedBiomarkersDisease ProgressionCross-Sectional StudiesAmyloid beta-Peptidestau ProteinsAged, 80 and overLongitudinal StudiesPeptide Fragments

Stichwörter der Autor:innen

Alzheimer diseasecerebrospinal fluid biomarkersdementia riskfunctional impairmentsymptom persistence

Substanzen

BiomarkersAmyloid beta-Peptidestau ProteinsPeptide Fragments

Autor:innen und Institutionen

  • Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Eric E Smith, Zahinoor Ismail

Förderung

  • NIHR Exeter Biomedical Research Centre
  • Gordie Howe CARES
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Ghahremani, M., Smith, E. E., & Ismail, Z. (2026). Persistent Functional Impairment as an Early Indicator of Alzheimer Disease Pathology and Progression. Journal of the American Geriatrics Society, 74(2), 447-457. https://doi.org/10.1111/jgs.70247

Vancouver

Ghahremani M, Smith EE, Ismail Z. Persistent Functional Impairment as an Early Indicator of Alzheimer Disease Pathology and Progression. Journal of the American Geriatrics Society. 2026;74(2):447-457. doi:10.1111/jgs.70247

BibTeX
@article{Ghahremani2026,
  author = {Ghahremani, Maryam and Smith, Eric E and Ismail, Zahinoor},
  title = {Persistent Functional Impairment as an Early Indicator of Alzheimer Disease Pathology and Progression},
  journal = {Journal of the American Geriatrics Society},
  year = {2026},
  volume = {74},
  number = {2},
  pages = {447--457},
  doi = {10.1111/jgs.70247}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche